Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Ford & Associates Nationwide Legal Services, A.P.C., Provides Research Commentary on Zofran Birth Defect Allegations in Light of Two Recently Filed 2015 Lawsuits
  • USA - English


News provided by

Ford & Associates Nationwide Legal Services, A.P.C.

Mar 13, 2015, 14:45 ET

Share this article

Share toX

Share this article

Share toX


San Diego, CA (PRWEB) March 13, 2015 -- In wake of two February 2015 filed lawsuits: case number 1:15-cv-10429, U.S. District Court, District of Massachusetts; and case number 2:15-cv-00709PD, United States District Court of the Eastern District of Pennsylvania, Ford & Associates provides research commentary on the allegations that GlaxoSmithKline (GSK) was aware of Zofran's potential pregnancy dangers, including fetal heart defects and other congenital abnormalities, but did not warn consumers of such dangers.

Ford & Associates has researched the birth defect allegations being brought against GlaxoSmithKline, and has added information to the firm's website for those wanting to learn more about Zofran, and potential side effects associated with the drug.

Post this

“Ford & Associates has researched the birth defect allegations being brought against GSK, to which we have added pertinent information to our website in regard to recent (February 2015) lawsuits filed for those wanting to learn more about Zofran, and potential side effects associated with the drug. We are interested in talking with women who took Zofran during their pregnancy, and may have incurred injuries to themselves or their baby as a result.” - Mateo Martinez, Ford & Associates Case Manager

Zofran (ondansetran) is in a class of medications called 5-HT3 receptor antagonists, and was approved by the FDA in 1991 to treat nausea and vomiting in patients undergoing surgery or cancer treatments. However, the drug is often prescribed off-label to treat nausea and vomiting in pregnant women. Ford & Associates has learned that while Zofran's application was extended by the FDA to treat nausea in post-operative patients, the FDA never approved Zofran to treat nausea and vomiting during pregnancy.*

In addition, Ford & Associates notes that after multiple reports were received by the FDA’s Adverse Event Reporting System (FAERS) about alleged adverse Zofran side effects, in 2013, the FDA issued a warning against Zofran use during pregnancy. The FDA is continuing to research this issue to determine if any regulatory action is required.**

Two recently filed February 2015 lawsuits (case numbers 1:15-cv-10429 and 2:15-cv-00709PD) allege that GlaxoSmithKline presented no evidence of Zofran's safety for unborn children, yet marketed the drug to treat morning sickness in pregnant women without FDA approval. According to court documents, the plaintiff in case 2:15-cv-00709PD, filed February 12th in the U.S. District Court in Pennsylvania, claims her use of Zofran during two of her pregnancies allegedly resulted in both children being born with heart defects.

According to court documents, the plaintiff in case 1:15-cv-10429, filed February 16th in the U.S. District Court, District of Massachusetts, claims her daughter was allegedly born with birth defects after the plaintiff used Zofran to treat nausea during her pregnancy. Further court documents in this case claim that GlaxoSmithKline was aware of laboratory studies that allegedly linked intrauterine deaths and malformations in animals that were administered Zofran.

Ford & Associates has also learned that in 2012, GlaxoSmithKline agreed to pay $3 billion to resolve charges with the U.S. Department of Justice regarding the alleged improper marketing and failure to report safety data on a number of medications, including Zofran (case number 11-10398-RWZ: United States ex. rel Greg Thorpe, ET AL vs. GlaxoSmithKline, LLC, filed July 2012).***

*accessdata.fda.gov/drugsatfda_docs/label/2012/020007s043lbl.pdf, FDA, January 1991
**fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm351864.htm, FDA, March 2013
***justice.gov/sites/default/files/opa/legacy/2012/07/02/us-complaint.pdf, USDOJ, July 2012

About Ford & Associates Nationwide Legal Services, A.P.C.
Ford & Associates Nationwide Legal Services, A.P.C., is a San Diego based injury firm that handles each case with unparalleled dedication, competence, and skill. Your case is their case, your fight is their fight, and no stone will be left unturned until a favorable outcome has been secured as allowed by law.

If you believe that your child has suffered birth defects from Zofran use during pregnancy, you may be entitled to file a claim against GlaxoSmithKline. For more information on Zofran, and answers to Zofran lawsuit questions, contact Ford & Associates today at 1-866-242-0905 for a free, no-obligation case review.

Ford & Associates Nationwide Legal Services, A.P.C.
3555 4th Ave
San Diego, CA 92103
866-242-0905

ATTORNEY ADVERTISING. © 2015 Ford & Associates Nationwide Legal Services, A.P.C.. The law firm responsible for this advertisement is Ford & Associates Nationwide Legal Services, A.P.C., 3555 Fourth Avenue, San Diego, California 92103, 866-242-0905. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Mateo Martinez, Ford & Associates Nationwide Legal Services, A.P.C., http://drug-lawsuits.com, +1 866-242-0905, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.